Date:6/13/2011

of the date of this press release, and involve certain risks and uncertainties. Forward looking statements include statements herein with respect to the successful execution of the Company's strategy, including with respect to the growth expectations at its Erye subsidiary, about which no assurances can be given. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors including the effects of competition from larger nationally and privately owned suppliers and others in the markets that Erye serves, the effects of the National Essential Drug System and other changes in the Chinese regulatory environment and anticipated pressure on pricing from such system and changes, Erye's ability to maintain sales and margins of its historic products which have been on the market for a number of years, Erye's ability to acquire or develop new drug products and obtain regulatory approvals for their distribution, Erye's ability to maintain margins notwithstanding increased human resources and other costs, including the costs of a larger facility, Erye's ability to generate free cash flow notwithstanding future plant expansion and other capital needs, the ability of the Company to realize on its investment in Erye through distributions, divestiture or other strategic alternatives, and the "Risk Factors" described in the Company's Annual Report on Form 10-K  filed with the Securities and Exchange Commission on April 6, 2011, as well as other periodic filings made with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

For more information, please contact:
NeoStem, Inc.
Robin Smith, CEO
Phone: +1 (212) 584-4174
E-mail: rsmith@neostem.com
http://www.neostem.c
'/>"/>

SOURCE NeoStem, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. On World AIDS Day, CHF International Calls for Community Mobilization and Local Capacity Building to Fight HIV/AIDS
2. Reduced Lung Capacity Accelerates With Diabetes
3. InterMune to Announce Results of Phase 3 CAPACITY Program of Pirfenidone in IPF Tomorrow, February 3
4. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
5. Millstone Medical Outsourcing Opens New, Advanced Clean Room to Expand Capacity for Sterile Packaging
6. Safe Life Ramps Production Capacity of Comfortable, Breathable N95 Respirator Amid Worldwide Shortage
7. New Technology Center Increases B. Brauns Infusion Pump Capacity
8. NVHA and Inova Health System Utilize Philips VISICU eICU® Program to Increase Surge Capacity During All-Hazards Event
9. InspireMD Boosts MGuard Production Capacity
10. Anodizing Leader Expands Capacity at U.S. Facility
11. Millstone Medical Outsourcing Expands Sales, Marketing Capacity, Hires Two Professionals